MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. "The addition of Scot to our sales and distribu ...

MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distr ...

Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to ...

Core Insights - PetVivo Holdings, Inc. has appointed Eric Samples as the new Field Veterinary Business Development Manager, focusing on Ohio, Pennsylvania, and the Baltimore/DC area [1][2] - Eric Samples brings over 25 years of experience in human and animal health sales, having previously worked with Covetrus and other major pharmaceutical companies [2][5] - The company aims to enhance awareness of its flagship product, Spryng™ with OsteoCushion™ technology, which is designed to manage lameness and joint-related issues in animals [2][3] Company Overview - PetVivo Holdings, Inc. is a biomedical device company that specializes in innovative medical devices and therapeutics for companion animals [4] - The company has a strategy focused on developing and commercializing human therapies for companion animals efficiently, allowing for quicker market entry compared to human pharmaceuticals [4] - PetVivo has a robust pipeline of products and holds a portfolio of 21 patents protecting its biomaterials and production processes [5] Product Information - The flagship product, Spryng™ with OsteoCushion™ Technology, is an intra-articular injectable aimed at managing lameness and joint-related afflictions, including osteoarthritis, in various animals [5]

MINNEAPOLIS, MN, US, Aug. 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2024. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question- ...

"In fiscal 2024, we reported strong financial and operational progress, including revenues up 6% to $969,000," commented PetVivo CEO, John Lai. "Our revenue growth was driven largely by our expanded distributor network, with sales of Spryng™ by distributors up 15% to $732,000. This helped drive our gross profit up 6% to $740,000, with our gross margins improving 40 basis points to 76.3%. "Also during the year, we developed clinical data on the safety and efficacy of Spryng, increased distribution through th ...

Market Information Dividends From January 2024 to March 2024, the Company issued 324,000 shares of common stock to four consultants for services provided to the Company valued at $333,660. All of these transactions described above were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering. The purchasers of securities in each of these transactions represented their intention to acquire securities for i ...

Fiscal 2024 Financial Highlights Fiscal 2024 Operational Highlights Management Commentary "Also during the year, we developed clinical data on the safety and efficacy of Spryng, increased distribution through the addition of Covetrusm, expanded our efforts with MWI, and increased market awareness of Spryng to veterinarians. "The release of tolerance clinical results involving the injection of Spryng into the joints of canines and felines have confirmed the long-known understanding that Spryng is a safe opti ...

PetVivo management will host the presentation, followed by a question-and-answer period. If you require any assistance connecting to the call, please contact CMA at 1-949-432-7566. For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com. The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act ...

MINNEAPOLIS, MN, US, June 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has appointed Bryan Monninger to vice president of sales. In this new position, he will lead the PetVivo's sales and distribution teams, with a focus on expanding the market adoption of the company's innovative animal osteoarthritis medical product, Spryng™ with OsteoCushion™ Technology. Monninger b ...